FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891485401> ?p ?o ?g. }

• W2891485401 endingPage "292" @default.
• W2891485401 startingPage "287" @default.
• W2891485401 abstract "The current standard of care for patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) is high-dose conditioning followed by autologous stem cell transplantation (ASCT). For some patients (ie, those with highest-risk disease, insufficient stem cell numbers after mobilization, or bone marrow involvement) allogeneic hematopoietic cell transplantation (alloHCT) offers the potential for cure. However, the majority of patients undergoing alloHCT receive reduced-intensity conditioning as a preparative regimen, and studies assessing outcomes of patients after alloHCT with myeloablative conditioning are limited. In this retrospective study, we reviewed outcomes of 22 patients with recurrent and refractory NHL who underwent alloHCT with myeloablative BEAM conditioning and received tacrolimus/sirolimus as graft-versus-host disease (GVHD) prophylaxis at City of Hope between 2005 and 2018. With a median follow-up of 2.6 years (range, 1.0 to 11.2 years), the probabilities of 2-year overall survival and event-free survival were 58.3% (95% confidence interval [CI], 35.0% to 75.8%) and 45.5% (95% CI, 24.4% to 64.3%), respectively. The cumulative incidence of grade II to IV acute GVHD was 45.5% (95% CI, 23.8% to 64.9%), with only 1 patient developing grade IV acute GVHD. However, chronic GVHD was seen in 55% of the patients (n = 12). Of the 22 eligible patients, 2 had undergone previous ASCT and 2 had undergone previous alloHCT. Both patients with previous ASCT developed severe regimen-related toxicity. Patients who underwent alloHCT with chemorefractory disease had lower survival rates, with 1-year OS and EFS of 44.4% and 33.0%, respectively. In conclusion, alloHCT with a BEAM preparative regimen and tacrolimus/sirolimus-based GVHD should be considered as an alternative option for patients with highest-risk lymphoma whose outcomes are expectedly poor after ASCT." @default.
• W2891485401 created "2018-09-27" @default.
• W2891485401 creator A5001128287 @default.
• W2891485401 creator A5004358801 @default.
• W2891485401 creator A5013307217 @default.
• W2891485401 creator A5030788778 @default.
• W2891485401 creator A5030822207 @default.
• W2891485401 creator A5039374832 @default.
• W2891485401 creator A5052032114 @default.
• W2891485401 creator A5059392609 @default.
• W2891485401 creator A5063345064 @default.
• W2891485401 creator A5063781871 @default.
• W2891485401 creator A5065052780 @default.
• W2891485401 creator A5070193149 @default.
• W2891485401 creator A5075903729 @default.
• W2891485401 creator A5086494836 @default.
• W2891485401 date "2019-02-01" @default.
• W2891485401 modified "2023-09-26" @default.
• W2891485401 title "Outcomes of Patients with Recurrent and Refractory Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation with BEAM Conditioning and Sirolimus- and Tacrolimus-Based GVHD Prophylaxis" @default.
• W2891485401 cites W1049067418 @default.
• W2891485401 cites W1972184826 @default.
• W2891485401 cites W1993486845 @default.
• W2891485401 cites W1997353354 @default.
• W2891485401 cites W2008349138 @default.
• W2891485401 cites W2019874087 @default.
• W2891485401 cites W2021130630 @default.
• W2891485401 cites W2027086946 @default.
• W2891485401 cites W2028249508 @default.
• W2891485401 cites W2035210318 @default.
• W2891485401 cites W2047257824 @default.
• W2891485401 cites W2055981604 @default.
• W2891485401 cites W2062437906 @default.
• W2891485401 cites W2064085613 @default.
• W2891485401 cites W2064378168 @default.
• W2891485401 cites W2066175494 @default.
• W2891485401 cites W2067030239 @default.
• W2891485401 cites W2072854641 @default.
• W2891485401 cites W2078782557 @default.
• W2891485401 cites W2079433846 @default.
• W2891485401 cites W2080986723 @default.
• W2891485401 cites W2085459287 @default.
• W2891485401 cites W2101802089 @default.
• W2891485401 cites W2112632101 @default.
• W2891485401 cites W2123069998 @default.
• W2891485401 cites W2125616358 @default.
• W2891485401 cites W2132589242 @default.
• W2891485401 cites W2133934152 @default.
• W2891485401 cites W2140253250 @default.
• W2891485401 cites W2150587745 @default.
• W2891485401 cites W2155616447 @default.
• W2891485401 cites W2156056890 @default.
• W2891485401 cites W2157717016 @default.
• W2891485401 cites W2165885469 @default.
• W2891485401 cites W2176208873 @default.
• W2891485401 cites W2232371609 @default.
• W2891485401 cites W2307073326 @default.
• W2891485401 cites W2344483783 @default.
• W2891485401 cites W2398011965 @default.
• W2891485401 cites W2532606512 @default.
• W2891485401 cites W2598700764 @default.
• W2891485401 cites W2609973112 @default.
• W2891485401 cites W2744261860 @default.
• W2891485401 cites W2773804840 @default.
• W2891485401 cites W2794872274 @default.
• W2891485401 doi "https://doi.org/10.1016/j.bbmt.2018.09.009" @default.
• W2891485401 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6502508" @default.
• W2891485401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30227232" @default.
• W2891485401 hasPublicationYear "2019" @default.
• W2891485401 type Work @default.
• W2891485401 sameAs 2891485401 @default.
• W2891485401 citedByCount "5" @default.
• W2891485401 countsByYear W28914854012019 @default.
• W2891485401 countsByYear W28914854012020 @default.
• W2891485401 countsByYear W28914854012022 @default.
• W2891485401 countsByYear W28914854012023 @default.
• W2891485401 crossrefType "journal-article" @default.
• W2891485401 hasAuthorship W2891485401A5001128287 @default.
• W2891485401 hasAuthorship W2891485401A5004358801 @default.
• W2891485401 hasAuthorship W2891485401A5013307217 @default.
• W2891485401 hasAuthorship W2891485401A5030788778 @default.
• W2891485401 hasAuthorship W2891485401A5030822207 @default.
• W2891485401 hasAuthorship W2891485401A5039374832 @default.
• W2891485401 hasAuthorship W2891485401A5052032114 @default.
• W2891485401 hasAuthorship W2891485401A5059392609 @default.
• W2891485401 hasAuthorship W2891485401A5063345064 @default.
• W2891485401 hasAuthorship W2891485401A5063781871 @default.
• W2891485401 hasAuthorship W2891485401A5065052780 @default.
• W2891485401 hasAuthorship W2891485401A5070193149 @default.
• W2891485401 hasAuthorship W2891485401A5075903729 @default.
• W2891485401 hasAuthorship W2891485401A5086494836 @default.
• W2891485401 hasBestOaLocation W28914854011 @default.
• W2891485401 hasConcept C126322002 @default.
• W2891485401 hasConcept C141071460 @default.
• W2891485401 hasConcept C2777408962 @default.
• W2891485401 hasConcept C2779338263 @default.
• W2891485401 hasConcept C2781413609 @default.
• W2891485401 hasConcept C2909675724 @default.
• W2891485401 hasConcept C2911091166 @default.

• next